MEDINNO
Latest round
- Series B
Last raised
- Nov 2020
Total raised
- $20M
Investors
- 1
About MEDINNO
Based in Seoul, South Korea, and founded by Kyungmin Joo in 2018, MEDINNO Inc. operates as a biotechnology company specializing in the development of stem cell treatments. The firm as of October 2023, has a production facility in Seoul, and an R&D center in Gyeonggi-do, South Korea. In August 2026, MEDINNO Inc. The biopharmaceutical company specializes in the development of cell therapeutics, with an emphasis on Mesenchymal Stem Cells (MSCs), for brain diseases. These stem cells are derived from the umbilical cords of healthy newborns, offering a promising avenue for the treatment of brain diseases. MEDINNO’s flagship product is HIEstem, which is created through Thrombin pre-conditioning, a global patented technology. HIEstem showcases significant neuroprotective effects, including the inhibition of gliosis and inflammation, reducing brain damage, and promoting functional recovery. This product is primarily aimed at treating conditions like Hypoxic Ischemic Encephalopathy (HIE) and Intraventricular Hemorrhage (IVH). Additionally, as of October 2023, the firm is working on the development of Adult Human Neural Stem Cell therapeutics for treating spinal cord injury and strokes, and gene therapies using stem cells for treating Multiple Sclerosis and Brain Tumor.
Who invested in MEDINNO
1 investor across 3 rounds
See all investors in MEDINNO
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about MEDINNO
Who invested in MEDINNO?
MEDINNO has 1 investor on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has MEDINNO raised?
MEDINNO has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did MEDINNO last raise money?
MEDINNO's most recent round on record is a Series B, in Nov 2020.
What does MEDINNO do?
Based in Seoul, South Korea, and founded by Kyungmin Joo in 2018, MEDINNO Inc.
Where is MEDINNO headquartered?
MEDINNO is headquartered in Seoul, South Korea.
Which VCs invest in companies like MEDINNO?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at MEDINNO's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like MEDINNO? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.